Skip to main content
Premium Trial:

Request an Annual Quote

Foundation Medicine, Incyte Partner on CDx Development

NEW YORK (GenomeWeb) – Foundation Medicine and Incyte have partnered to develop and commercialize companion diagnostics, the companies said today.

The initial focus will be on developing a CDx for Incyte's FGFR1/2/3 inhibitor, pemigatinib, to treat patients with cholangiocarcinoma. This will include the detection of activating FGFR2 translocations. The companies expect to incorporate the CDx into Foundation Medicine's existing US Food and Drug Administration-approved assay, FoundationOne CDx.

Steven Stein, Incyte's chief medical officer, said in a statement that Incyte is currently evaluating pemigatinib in metastatic or surgically unresectable cholangiocarcinoma patients as part of the FIGHT (fibroblast growth factor receptor in oncology and hematology trials) clinical development program and plans to present initial data at the European Society for Medical Oncology meeting next month.

"We're committed to helping our biopharma partners bring biomarker-driven therapies to cancer patients," said Melanie Nallicheri, chief business officer and head of biopharma at Foundation Medicine, in a statement.

Foundation Medicine recently became a wholly-owned subsidiary of Roche. The company has CDx development and research agreements with several other pharmaceutical companies, including Merck, Chugai Pharmaceutical, Bristol-Myers Squib, and Pfizer.

The Scan

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.

Clinical Trial Participants, Investigators Point to Importance of Clinical Trial Results Reporting in Canadian Study

Public reporting on clinical trial results is crucial, according to qualitative interviews with clinical trial participants, investigators, and organizers from three provinces appearing in BMJ Open.

Old Order Amish Analysis Highlights Autozygosity, Potential Ties to Blood Measures

Researchers in BMC Genomics see larger and more frequent runs-of-homozygosity in Old Order Amish participants, though only regional autozygosity coincided with two blood-based measures.

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.